Tenecteplase for Acute Non–Large Vessel Occlusion After Ischemic Stroke

The article discusses the OPTION trial, which evaluated intravenous tenecteplase. This drug was administered to patients with ischemic stroke within a time window of 4.5 to 24 hours from symptom onset. Patients were selected based on CT perfusion imaging. The OPTION study addresses an important question in acute stroke care. Nevertheless, its findings warrant cautious interpretation. The reasons for this caution include safety considerations and the overall clinical context. The text is a letter to the editor, expressing interest in the study while also highlighting the need for prudence in interpreting its results.